Now that Definium Therapeutics Inc. (DFTX) has reported positive results from its Phase 3 Emerge trial, greater clarity has emerged around the clinical profile and potential of its lead investigational asset, DT120 Orally Disintegrating Tablet.
Emerge is the company's first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 mcg in adults with major depressive disorder (MDD).
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.